A Phase II, Open Label, Dose Escalation Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2018
At a glance
- Drugs MABp1 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors XBiotech
- 13 Sep 2018 Results published in the XBiotech Media Release
- 13 Sep 2018 According to a XBiotech media release, announced that it has completed the first cohort of its open label pilot study in Atopic Dermatitis.In the first phase of the study, 9 patients received a low dose over a short course of treatment.Multiple secondary endpoints used to assess efficacy showed significant improvements.The study will now begin enrollment of 20 patients to receive 400mg weekly doses over an 8 week treatment period.
- 29 Aug 2018 Planned number of patients changed from 20 to 29.